Novo Nordisk partners with Variant Bio, paying up to $50M upfront for metabolic disease targets. Some funds will support Indigenous communities that provided data.

Looking to expand its legacy in metabolic conditions, Novo Nordisk has inked a multiyear research pact with Variant Bio to better understand the genetics underlying disease across diverse populatio | ...

Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a ...

Dual- and triple-agonist GLP-1s appear to achieve greater weight loss in an overview of clinical trials of approved and ...

Novo Nordisk faces scrutiny over UK pharmacy sponsorships tied to weight-loss drugs, with critics citing conflicts of interest and regulatory breaches.

This article introduces the largest foundations in the world, fostering changes and improvements across various sectors to ...

Variant Bio, a small biotech company based in Seattle, is using genetic information from Indigenous people to develop drugs ...

Lawmakers on Thursday will hear testimony on a bill to lower the price of insulin drugs and supplies for more North Dakotans.

Kuykendall has been in his current role since July 2022. Interesting fact: He has worked with Novo Nordisk for more than 18 ...

As previously reported, Bernstein upgraded Novo Nordisk (NVO) to Market Perform from Underperform with a price target of DKK 600, up from DKK ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 492.13% and ...